LIP5 Inhibitors
LIP5 inhibitors listed include various classes of compounds such as morpholine derivatives, steroidal metabolites, synthetic inhibitors targeting MEK enzymes, pyridinyl imidazole derivatives that selectively inhibit p38 MAP kinase, anthrapyrazolone inhibitors which target JNK, and small molecule inhibitors that inhibit specific GTPases. Additionally, the list contains selective inhibitors that target ROCK, inhibitors which impede V-ATPase function, and irreversible pan-caspase inhibitors exemplified by Z-VAD-FMK. Each of these compounds can alter cellular processes such as PI3K signaling, MAPK/ERK and p38 MAP kinase pathways, cytoskeletal organization, vesicle trafficking, endosomal acidification, and apoptosis, all of which are relevant to the cellular context in which LIP5 operates.
These chemicals can influence the functional landscape of LIP5 by affecting the upstream signaling events or by modifying the cellular environment that is critical for LIP5's activity. For instance, PI3K inhibitors can disrupt membrane dynamics, which is a fundamental aspect for proteins involved in vesicle formation and trafficking, potentially altering the normal operation of LIP5. Similarly, inhibitors of the MAPK/ERK pathway can change the endocytic trafficking pathways, thereby influencing LIP5's activity. Inhibitors disrupt GTPase-mediated signaling, affecting actin polymerization and vesicle movement, which could impact the processes where LIP5 is involved. By influencing the cytoskeleton can affect vesicle trafficking and membrane remodeling, which are important for LIP5's role in the cell. Lastly, inhibitors of vesicle trafficking and acidification can significantly modify the vesicular pathways and endosomal functions, which could in turn affect LIP5's role in these processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a morpholine derivative and a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators of various cellular processes including those potentially involving LIP5. Inhibition of PI3K can alter membrane trafficking and protein sorting, thereby affecting LIP5 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a steroidal metabolite that acts as a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, it can disrupt pathways that indirectly affect LIP5 activity related to membrane dynamics and endosomal sorting. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a synthetic compound that selectively inhibits MEK, which is part of the MAPK/ERK pathway. As this pathway can intersect with endosomal sorting routes where LIP5 may be involved, MEK inhibition can result in altered endocytic trafficking affecting LIP5's functional context. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a pyridinyl imidazole derivative that selectively inhibits p38 MAP kinase. The p38 MAP kinase pathway is implicated in cytokine production and apoptosis, processes that can affect cellular homeostasis and potentially the functional environment of LIP5. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK). Inhibition of JNK can influence transcriptional events and cellular stress responses, which can alter the cellular context in which LIP5 operates, such as vesicular trafficking and protein stability. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766 is a small molecule inhibitor of the Rac1 GTPase. Rac1 is involved in actin cytoskeleton organization and membrane ruffling, which are processes related to vesicle trafficking and could therefore indirectly affect the function of LIP5 in the cell. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). ROCK is implicated in cytoskeletal arrangement, which is fundamental to vesicle trafficking and membrane remodeling, processes that can be linked to LIP5's functional role in the cell. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a macrolide antibiotic that functions as a specific inhibitor of the V-ATPase proton pump. By blocking V-ATPase, bafilomycin A1 can disrupt endosomal acidification and vesicle trafficking, which can indirectly impact the cellular context of LIP5. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a small molecule that inhibits dynamin, a GTPase involved in vesicle scission from the plasma membrane. As dynamin is crucial for endocytosis, dynasore can disrupt endocytic pathways and potentially affect the functional role of LIP5 in vesicle trafficking. | ||||||